Bristol-Myers Squibb's Blockbuster Immunotherapy Opportunity

Recently published long-term survival data for nivolumab is so promising that short term concerns seem trivial.

Mar 6, 2014 at 2:30PM

Bristol-Myers Squibb (NYSE:BMY) won more attention for its anti-PD1 cancer immunotherapy program over some recently published long term survival data. An editorial in the Journal of Clinical Oncology compared nivolumab with the company's commercially successful Yervoy. It looks like Bristol-Myers may have a real winner on its hands.

Losing the race
Sadly for Bristol-Myers, nivolumab probably won't be the first PD-1 drug approved for the advanced melanoma indication. Merck (NYSE:MRK) is driving MK-3475 at full throttle. R&D Chief Roger Perlmutter is back at Merck for reasons that caused him to leave for Amgen (NASDAQ:AMGN) more than a decade ago. One of them is an ability to race toward approval of top-priority drugs. Although Bristol-Myers has accumulated far more data for nivolumab, Merck has already started a rolling submission of MK-3475 for advanced melanoma that should be complete in the first half of this year.

Merck is also charging forward with a combination study of MK-3475 and Amgen's talimogene laherparepvec, or T-Vec. Amgen's interesting therapy is a virus designed to infect tumor cells specifically. Once inside, it causes tumor cells to signal the immune system while replicating itself until the cell eventually bursts.

Winning in the clinic
Bristol-Myers might finish second in the race to win approval for a PD-1 drug, but it definitely has the most clinical data. The recently released, long-term survival figures that has the research community excited come from 107 advanced melanoma patients in a phase 1 nivolumab trial that ended in 2012. Most of them received at least two previous therapies. Median OS was 16.8 months, with a one-year survival rate of 62%, and a two-year survival rate of 43%.

To put that in perspective, let's compare it to a trial with similar patients receiving gp100 vaccine alone, Yervoy, or both. Among patients receiving Yervoy, an estimated 21.6% to 23.5% of patients were alive at 24 months versus 13.7% of patients receiving gp100 alone. The presence of the experimental vaccine clouds the comparison a bit, but it looks like nivolumab's two-year survival rate is almost twice as high as Yervoy's.

Beyond survival
Nivolumab's advantage doesn't stop at survival data. The anti-PD-1 therapy appears much more easily tolerated. Both Yervoy and nivolumab prevent tumor cells from shutting down a local immune attack, but they act on different targets. It seems that Yervoy's inhibition of the anti-CTLA-4 pathway has an effect on healthy tissues as well as tumors.

A third advantage for nivolumab is the durability of its response. Although the trial ended in 2012, some patients began dosing years earlier. Investigators have data on patients going back more than four years, the longest for melanoma patients treated with an anti-PD-1 therapy. Many had tumors that remained the same size, or continued to shrink after treatment ended.

Typically, when advanced melanoma patients experience new tumors after a period of remission, the disease returns at full strength. When patients previously treated with nivolumab experienced new growths, they remained small. It seems that the immune system may continue to keep the disease under control even after therapy has ended.

Combination or cannibalization?
2013 was Yervoy's third year on the market. It reached $960 million, and it's still growing. Unfortunately, nivolumab is under development for the treatment of advanced melanoma, Yervoy's territory. If the more effective, and better tolerated PD-1 is approved as a solo therapy, we can expect it to cut heavily into Yervoy sales.

Of course this problem would be solved if regulators approved a Yervoy and nivolumab combination therapy for advanced melanoma or other cancers. In late January, Bristol-Myers gave some fairly cool remarks regarding late stage combination studies, and the stock sank more than 10% over the next several days. When the company announced it would begin late stage combo studies on March 4, all was forgiven and shares returned to a 12-month high.

Foolish final take
Merck and Bristol-Myers are likely to compete heavily for advanced melanoma patients in the near term. So far, both therapies look like they are effective beyond skin cancers. Going forward several years, there should be plenty of room in other indications. In the meantime, analysts on Wall Street will likely keep making a fuss over who's first to bring a PD-1 to market, and whether or not nivolumab will cannibalize Yervoy. A savvy investor might view these trivial concerns as opportunities to buy a stock with serious long-term potential.

Even better potential growth opportunities
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Cory Renauer has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers